Laidlaw downgraded MEI Pharma to Hold from Buy without a price target after the company’s board determined to begin evaluation of strategic alternatives, including potential transactions as well as an orderly wind down of its operation. Given the uncertainty of the company’s future, including a possible total shut down, the firm downgraded the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEIP: